Prognostic value of LAMP3 and TP53 overexpression in benign and malignant gastrointestinal tissues

Oncotarget

Volumn 5, Issue 23, 2014, Pages 12398-12409

  Sun, Rongwei ^a   Wang, Xudong ^a   Zhu, Huijun ^a   Mei, Haijun ^a   Wang, Wei ^a   Zhang, Shu ^a   Huang, Jianfei ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Gastrointestinal cancer; LAMP3; Prognosis; TP53

Indexed keywords

DENDRITIC CELL LYSOSOME ASSOCIATED MEMBRANE PROTEIN; PROTEIN P53; LAMP3 PROTEIN, HUMAN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; TP53 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; BENIGN TUMOR; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STOMACH CANCER; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; AGED; BIOSYNTHESIS; GASTROINTESTINAL TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; BIOMARKERS, TUMOR; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84919925517     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2643     Document Type: Article

References (39)

1. Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014; 40(3):250-260.
2. Rahman R, Asombang AW and Ibdah JA. Characteristics of gastric cancer in Asia. World J Gastroenterol. 2014; 20(16):4483-4490.
3. Peleteiro B, Bastos A, Ferro A and Lunet N. Prevalence of Helicobacter pylori Infection Worldwide: A Systematic Review of Studies with National Coverage. Dig Dis Sci. 2014; 59(8):1698-1709.
4. Lu B and Li M. Helicobacter pylori eradication for preventing gastric cancer. World J Gastroenterol. 2014; 20(19):5660-5665.
5. Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, Van Cutsem E, van de Velde C and Cervantes A. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat Rev. 2014; 40(6):692-700.
6. Zhu X and Li J. Gastric carcinoma in China: Current status and future perspectives (Review). Oncol Lett. 2010; 1(3):407-412.
7. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006; 12(1):17-20.
8. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90.
9. Yu Y, Zheng S, Zhang S, Jin W, Liu H, Jin M, Chen Z, Ding Z, Wang L and Chen K. Polymorphisms of inflammationrelated genes and colorectal cancer risk: a population-based case-control study in China. Int J Immunogenet. 2014; 41(4):289-297.
10. Xu AG, Yu ZJ, Jiang B, Wang XY, Zhong XH, Liu JH, Lou QY and Gan AH. Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol. 2010; 16(8):960-965.
11. de Saint-Vis B, Vincent J, Vandenabeele S, Vanbervliet B, Pin JJ, Ait-Yahia S, Patel S, Mattei MG, Banchereau J, Zurawski S, Davoust J, Caux C and Lebecque S. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity. 1998; 9(3):325-336.
12. Ozaki K, Nagata M, Suzuki M, Fujiwara T, Ueda K, Miyoshi Y, Takahashi E and Nakamura Y. Isolation and characterization of a novel human lung-specific gene homologous to lysosomal membrane glycoproteins 1 and 2: significantly increased expression in cancers of various tissues. Cancer Res. 1998; 58(16):3499-3503.
13. Nagelkerke A, Bussink J, Mujcic H, Wouters BG, Lehmann S, Sweep FC and Span PN. Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response. Breast Cancer Res. 2013; 15(1):R2.
14. Mujcic H, Nagelkerke A, Rouschop KM, Chung S, Chaudary N, Span PN, Clarke B, Milosevic M, Sykes J, Hill RP, Koritzinsky M and Wouters BG. Hypoxic activation of the PERK/eIF2alpha arm of the unfolded protein response promotes metastasis through induction of LAMP3. Clin Cancer Res. 2013; 19(22):6126-6137.
15. Pennati M, Lopergolo A, Profumo V, De Cesare M, Sbarra S, Valdagni R, Zaffaroni N, Gandellini P and Folini M. miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochem Pharmacol. 2014; 87(4):579-597.
16. Nagelkerke A, Bussink J, van der Kogel AJ, Sweep FC and Span PN. The PERK/ATF4/LAMP3-arm of the unfolded protein response affects radioresistance by interfering with the DNA damage response. Radiother Oncol. 2013; 108(3):415-421.
17. Nagelkerke A, Sieuwerts AM, Bussink J, Sweep FC, Look MP, Foekens JA, Martens JW and Span PN. LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy. Endocr Relat Cancer. 2014; 21(1):101-112.
18. Nagelkerke A, Mujcic H, Bussink J, Wouters BG, van Laarhoven HW, Sweep FC and Span PN. Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer. Cancer. 2011; 117(16):3670-3681.
19. Kanao H, Enomoto T, Kimura T, Fujita M, Nakashima R, Ueda Y, Ueno Y, Miyatake T, Yoshizaki T, Buzard GS, Tanigami A, Yoshino K and Murata Y. Overexpression of LAMP3/TSC403/DC-LAMP promotes metastasis in uterine cervical cancer. Cancer Res. 2005; 65(19):8640-8645.
20. Zhai X, Zhu H, Wang W, Zhang S, Zhang Y and Mao G. Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC. Med Oncol. 2014; 31(6):970.
21. Hollstein M, Sidransky D, Vogelstein B and Harris CC. p53 mutations in human cancers. Science. 1991; 253(5015):49-53.
22. Vogelstein B and Kinzler KW. p53 function and dysfunction. Cell. 1992; 70(4):523-526.
23. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B and Slamon DJ. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 1996; 13(9):1971-1981.
24. Havrilesky L, Darcy K M, Hamdan H, Priore RL, Leon J, Bell J and Berchuck A. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003; 21(20):3814-3825.
25. Bellini MF, Cadamuro AC, Succi M, Proenca MA and Silva AE. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012; 2012:891961.
26. Jang BG and Kim WH. Molecular pathology of gastric carcinoma. Pathobiology. 2011; 78(6):302-310.
27. Xu HY, Xu WL, Wang LQ, Chen MB and Shen HL. Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a metaanalysis. PLoS One. 2014; 9(4):e95371.
28. Ishigami S, Ueno S, Matsumoto M, Okumura H, Arigami T, Uchikado Y, Setoyama T, Arima H, Sasaki K, Kitazono M, Shinchi H, Kijima Y and Natsugoe S. Prognostic value of CD208-positive cell infiltration in gastric cancer. Cancer Immunol Immunother. 2010; 59(3):389-395.
29. Adamsen BL, Kravik KL, Clausen OP and De Angelis PM. Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol. 2007; 31(6):1491-1500.
30. Liu J, Lu G, Li Z, Tang F, Liu Y and Cui G. Distinct compartmental distribution of mature and immature dendritic cells in esophageal squamous cell carcinoma. Pathol Res Pract. 2010; 206(9):602-606.
31. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, Bremond A, Goddard S, Pin JJ, Barthelemy-Dubois C and Lebecque S. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res. 2004; 10(22):7466-7474.
32. Chen J, Tang H, Wu Z, Zhou C, Jiang T, Xue Y, Huang G, Yan D and Peng Z. Overexpression of RBBP6, alone or combined with mutant TP53, is predictive of poor prognosis in colon cancer. PLoS One. 2013; 8(6):e66524.
33. Arriaga JM, Bravo IA, Bruno L, Morales Bayo S, Hannois A, Sanchez Loria F, Pairola F, Huertas E, Roberti MP, Rocca YS, Aris M, Barrio MM, Baffa Trasci S, Levy EM, Mordoh J and Bianchini M. Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer. Hum Pathol. 2012; 43(10):1695-1703.
34. Mojarad S, Venturini B, Fulgenzi P, Papaleo R, Brisigotti M, Monti F, Canuti D, Ravaioli A, Woo L, Dlay S and Sherbet GV. Prediction of nodal metastasis and prognosis of breast cancer by ANN-based assessment of tumour size and p53, Ki-67 and steroid receptor expression. Anticancer Res. 2013; 33(9):3925-3933.
35. Davidoff AM, Humphrey PA, Iglehart JD and Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A. 1991; 88(11):5006-5010.
36. Poon GM, Brokx RD, Sung M and Gariepy J. Tandem dimerization of the human p53 tetramerization domain stabilizes a primary dimer intermediate and dramatically enhances its oligomeric stability. J Mol Biol. 2007; 365(4):1217-1231.
37. Mujcic H, Rzymski T, Rouschop KM, Koritzinsky M, Milani M, Harris AL and Wouters BG. Hypoxic activation of the unfolded protein response (UPR) induces expression of the metastasis-associated gene LAMP3. Radiother Oncol. 2009; 92(3):450-459.
38. Detre S, Saclani Jotti G and Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995; 48(9):876-878.
39. Ni S, Xu L, Huang J, Feng J, Zhu H, Wang G and Wang X. Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer. Int J Clin Exp Pathol. 2013; 6(12):2887-2895.